Industries

Roche and Zealand advance petrelintide’s amylin approach to obesity

The Tip Desk · September 23, 2026 · 3 min read

Phase 2 findings and a planned combination study build the evidence for an alternative to incretin-only treatment.

Petrelintide, originally ZP8396 and also identified as RO7895515, is an investigational amylin analog developed for obesity. It offers a different mechanism from the incretin agonists dominating this series's approved comparator group. Roche and Zealand reported Phase 2 ZUPREME-1 findings in March 2026; the company release is a sponsor account, not a regulatory conclusion.

The ZUPREME-1 registry documents a placebo-controlled study of weekly subcutaneous treatment and a 28-week weight endpoint. The record is completed in the retrieved snapshot. A separate Phase 2 combination study pairs petrelintide with enicepatide and includes component and placebo comparisons over 40 weeks. That design can help separate combination effects from each component; it cannot yet supply an outcome while the study is not recruiting.

The major change in corporate backing came through the Zealand–Roche agreement. The agreement covers more than one development configuration; its full potential value is not a cash budget for this single trial.

Comparisons with approved obesity medicines still need to preserve duration, population and treatment-handling differences. Longer-term efficacy, tolerability and combination contribution remain evidence questions. Partnership revenue recognition makes Zealand's reported profit an unreliable shortcut for estimating recurring cash burn.

At June 30, Zealand held DKK 4.038 billion of cash and DKK 10.419 billion of marketable securities, totaling DKK 14.457 billion. First-half operating cash use was DKK 266 million, while reported profit was DKK 3.524 billion. Partnership revenue recognition and cash receipts occur on different schedules: the period included a $125 million Roche anniversary payment. Those effects make a simple annualized cash-burn calculation misleading. The report records DKK 312 million of borrowings; its detailed terms should be consulted before comparing this figure with another company's debt.

Roche reported CHF 5.448 billion of cash and equivalents and CHF 4.286 billion of other marketable liquidity at June 30, a combined CHF 9.734 billion. Total debt was CHF 31.805 billion; the company's net-debt measure was CHF 22.071 billion. First-half operating cash flow was CHF 7.635 billion and IFRS net income CHF 7.325 billion. The profitable group can fund research from operating businesses, but these figures do not disclose a dedicated budget for either obesity program. Its CHF 4.197 billion free-cash-flow measure is distinct from operating cash flow.

Roche and Zealand’s collaboration was announced in March 2025 and became effective in May. Zealand received $1.4 billion upfront in the second quarter of 2025. A further $250 million is scheduled across two anniversaries; the first $125 million was received in the first half of 2026. Potential development and sales milestones total up to $1.2 billion and $2.4 billion respectively and remain contingent.

The partners share profits and losses equally in the United States and Europe, with co-commercialization rights. Roche has exclusive commercialization rights elsewhere, where Zealand is eligible for tiered double-digit royalties reaching the high teens. Roche carries commercial manufacturing investment responsibilities. The program includes petrelintide alone and combinations with Roche's enicepatide; the agreement's aggregate economics should not be assigned wholly to the combination or treated as cash reserved for a single trial.

More on ZEAL

September 23, 2026 Drug Pipeline Roche and Zealand plan a two-mechanism obesity combination trial September 23, 2026 Drug Pipeline Lilly and Novo set the backdrop for a changing obesity pipeline

ZEAL — all coverage and financials